Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Two commonly used uveitis drugs perform similarly in NIH-funded clinical trial

11.09.2019

Methotrexate was more effective than mycophenolate mofetil at treating severe forms of the eye disease

Methotrexate and the more expensive mycophenolate mofetil performed similarly in a head-to-head clinical trial that compared the two drugs for treating noninfectious uveitis, an eye disease that accounts for up to 15% of blindness in the U. S.


Uveitis is inflammation of the eye originating in the uvea, which includes the iris, ciliary body, and the choroid. Anterior uveitis affects the iris; intermediate uveitis affects the ciliary body, posterior uveitis affects the choroid, and panuveitis affects multiple areas of the uvea.

Credit: Lesley Earl, National Eye Institute

Usage Restrictions: Image may be reused. Please credit National Eye Institute as the source.

In cases of more severe disease, posterior uveitis and panuveitis, the international trial showed that methotrexate was more effective in controlling inflammation. Investigators published results from the trial today in the Journal of the American Medical Association. The National Eye Institute, part of the National Institutes of Health, funded the trial.

"This study gives doctors and their patients with uveitis a starting point when considering treatment beyond corticosteroids," said lead study author Nisha Acharya, M.D., M.S., University of California, San Francisco.

Uveitis is inflammation of the eye's blood vessel-rich middle layer of tissue called the uvea. The condition can affect the iris (anterior uveitis), ciliary body (intermediate uveitis), and choroid (posterior uveitis) parts of the eye and is often chronic. Panuveitis affects multiple areas of the uvea.

Clinicians often first treat intermediate and posterior or panuveitis with oral corticosteroids like prednisone to control inflammation, but seek to quickly taper patients to a low dose and switch them to steroid-sparing drugs such as methotrexate and mycophenolate mofetil. Long-term, high-dose corticosteroid use risks serious side effects including osteoporosis, diabetes, and weight gain, and other eye problems including glaucoma and cataract. Other steroid alternatives such as biologics like adalimumab also carry serious side effects.

The First-line Antimetabolites for Steroid-sparing Treatment (FAST) Uveitis Trial enrolled and randomly assigned 216 patients with intermediate or posterior/panuveitis from India, the United States, Australia, Saudi Arabia and Mexico to methotrexate (107 participants) or mycophenolate (109 participants) treatment groups. Over six months, participants tapered to a maximum dose of 7.5 milligrams prednisone daily, while receiving either three grams oral mycophenolate daily or 25 milligrams methotrexate weekly. Participants reduced their dose, if necessary, to control adverse side effects such as nausea.

To assess control of inflammation, the research team performed clinical exams and ocular imaging in the front and back parts of the eye. They also checked visual acuity.

At six months, 67% of participants in the methotrexate group and 57% of participants in the mycophenolate group had controlled their inflammation and successfully tapered steroids. The remainder had the option to switch treatments. Differences in success rates between treatment groups were not statistically significant at six months.

At 12 months, 69% of participants who had switched from mycophenolate to methotrexate achieved treatment success, whereas only 35% of those participants who switched from methotrexate to mycophenolate achieved treatment success. Of the participants who continued with their original treatments, 80% on methotrexate and 74% on mycophenolate maintained inflammatory control at 12 months.

In patients with posterior or panuveitis, the most severe forms, 74% in the methotrexate group achieved control at six months, versus 55% in the mycophenolate group, indicating that methotrexate was significantly more effective at controlling inflammation for this subtype of uveitis.

Both methotrexate and mycophenolate mofetil, which are systemic and affect multiple cell types in the body, can cause side effects such as fatigue, nausea and headaches, but serious side effects are rare. Because participants were allowed to reduce dosage to control these side-effects, few of them dropped out of the FAST study due to their inability to tolerate the medication. Total rates of adverse events were similar between the two drugs.

"Based on this head-to-head clinical trial, methotrexate is as good as or better than mycophenolate for treating uveitis. That's important because the prior literature and a survey on treatment preferences suggests most clinicians believe the opposite. Now we have a randomized trial to provide guidance on treatment." said Acharya. "Additionally, there's a cost difference in the U.S. where mycophenolate to control uveitis is over five times more expensive."

###

For more information about uveitis, visit https://nei.nih.gov/health/uveitis.

This study was funded through NEI, Research to Prevent Blindness, and That Man May See Foundation. Clinical trial number NCT01829295. For more information visit https://clinicaltrials.gov/ct2/show/NCT01829295.

Reference: Rathinam SR, Gonzales JA, Thundikandy R, Kanakath A, Murugan SB, Vedhanayaki R, Lim LL, Suhler EB, Al-Dhibi HA, Doan T, Keenan J, Rao MM, Ebert CD, Nguyen HH, Kim E, Porco TC, and Acharya N. "Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial." Published online Sept 10, 2019, JAMA.

NEI leads the federal government's research on the visual system and eye diseases. NEI supports basic and clinical science programs to develop sight-saving treatments and address special needs of people with vision loss. For more information, visit https://www.nei.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit https://www.nih.gov/.

NIH...Turning Discovery Into Health®

Media Contact

Lesley Earl
neinews@nei.nih.gov
301-496-5248

 @nateyeinstitute

http://www.nei.nih.gov 

Lesley Earl | EurekAlert!

Further reports about: Uveitis drugs inflammation medical research methotrexate

More articles from Health and Medicine:

nachricht Researchers find new potential approach to type 2 diabetes treatment
11.11.2019 | Weill Cornell Medicine

nachricht Why beta-blockers cause skin inflammation
07.11.2019 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Magnets for the second dimension

If you've ever tried to put several really strong, small cube magnets right next to each other on a magnetic board, you'll know that you just can't do it. What happens is that the magnets always arrange themselves in a column sticking out vertically from the magnetic board. Moreover, it's almost impossible to join several rows of these magnets together to form a flat surface. That's because magnets are dipolar. Equal poles repel each other, with the north pole of one magnet always attaching itself to the south pole of another and vice versa. This explains why they form a column with all the magnets aligned the same way.

Now, scientists at ETH Zurich have managed to create magnetic building blocks in the shape of cubes that - for the first time ever - can be joined together to...

Im Focus: A new quantum data classification protocol brings us nearer to a future 'quantum internet'

The algorithm represents a first step in the automated learning of quantum information networks

Quantum-based communication and computation technologies promise unprecedented applications, such as unconditionally secure communications, ultra-precise...

Im Focus: Distorted Atoms

In two experiments performed at the free-electron laser FLASH in Hamburg a cooperation led by physicists from the Heidelberg Max Planck Institute for Nuclear physics (MPIK) demonstrated strongly-driven nonlinear interaction of ultrashort extreme-ultraviolet (XUV) laser pulses with atoms and ions. The powerful excitation of an electron pair in helium was found to compete with the ultrafast decay, which temporarily may even lead to population inversion. Resonant transitions in doubly charged neon ions were shifted in energy, and observed by XUV-XUV pump-probe transient absorption spectroscopy.

An international team led by physicists from the MPIK reports on new results for efficient two-electron excitations in helium driven by strong and ultrashort...

Im Focus: A Memory Effect at Single-Atom Level

An international research group has observed new quantum properties on an artificial giant atom and has now published its results in the high-ranking journal Nature Physics. The quantum system under investigation apparently has a memory - a new finding that could be used to build a quantum computer.

The research group, consisting of German, Swedish and Indian scientists, has investigated an artificial quantum system and found new properties.

Im Focus: Shedding new light on the charging of lithium-ion batteries

Exposing cathodes to light decreases charge time by a factor of two in lithium-ion batteries.

Researchers at the U.S. Department of Energy's (DOE) Argonne National Laboratory have reported a new mechanism to speed up the charging of lithium-ion...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

High entropy alloys for hot turbines and tireless metal-forming presses

05.11.2019 | Event News

Smart lasers open up new applications and are the “tool of choice” in digitalization

30.10.2019 | Event News

International Symposium on Functional Materials for Electrolysis, Fuel Cells and Metal-Air Batteries

02.10.2019 | Event News

 
Latest News

Magnets for the second dimension

12.11.2019 | Machine Engineering

New efficiency world record for organic solar modules

12.11.2019 | Power and Electrical Engineering

Non-volatile control of magnetic anisotropy through change of electric polarization

12.11.2019 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>